GlassScriptPhysician profile
Danielle Marie Thomas
NPI 1467209395
$826.63
in general payments reported to CMS, 2019-2025
12 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $599 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $237.52 | 2024 | Jakafi |
| Livanova USA, INC. | $148.06 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $131.81 | 2024 | Tecvayli, Darzalex |
| Sanofi Pasteur INC. | $74.92 | 2024 | |
| Astellas Pharma US INC | $49.59 | 2025 | Cresemba |
| E.R. Squibb & Sons, L.L.C. | $46.05 | 2024 | |
| Abbvie INC. | $45.38 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $25.16 | 2024 | Tecvayli, Talvey |
| Alexion Pharmaceuticals, INC. | $21.85 | 2024 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $17.07 | 2024 | Empaveli |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2024 | Calquence |
| Sobi, INC | $13.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.